U5P Stock Chart & Stats
€1.12
€0.01(0.89%)
At close: 4:00 PM EDT
€1.12
€0.01(0.89%)
Day’s Range― - ―
52-Week Range€0.74 - €1.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€96.81M
Enterprise Value€105.99
Total Cash (Recent Filing)€19.89M
Total Debt (Recent Filing)€17.86M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding90,203,354
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.32Price Target Upside196.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ExecutionCompleting enrollment and dosing ahead of schedule demonstrates effective clinical execution and keeps NPM-139 moving toward top-line data, an IND filing, and a planned Phase 2 study. This progress can improve development efficiency and preserve momentum in the lead program.
Strategic External ValidationNovo Nordisk’s evaluation provides meaningful external validation for Vivani’s semaglutide implant and NanoPortal technology. Although non-exclusive and not commercial revenue, the relationship may support credibility, technical assessment, and future partnering potential for the platform.
Long-acting Delivery PlatformA multi-month implant delivery model targets adherence and convenience challenges in chronic disease treatment. If clinical development succeeds, sustained dosing could differentiate Vivani’s products from repeated injections and create a reusable platform across several indications.
Bears Say
No Commercial RevenueThe absence of revenue shows Vivani has not yet established a commercial product or operating income stream. Near-term financial performance therefore remains dependent on clinical progress and access to capital rather than recurring customer demand or product sales.
Persistent Operating LossesPersistent losses near the mid-$20 million range indicate that development spending continues without a visible commercial earnings base. Unless pipeline programs advance successfully, ongoing losses can reduce equity and increase the need for financing before profitability is achievable.
Cash Burn And LeverageHeavy cash consumption combined with debt close to equity creates material funding pressure for a clinical-stage company. Continued trials and operating costs may require additional capital, while leverage can reduce flexibility and increase dilution or repayment risks.
Vivani Medical News
U5P FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was €0.73 and its highest was €1.60 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is €96.81M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Nov 18, 2026 which is in 62 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2026. The company reported -€0.061 earnings per share for the quarter, beating the consensus estimate of -€0.072 by €0.011.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.07.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 90,203,354 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -€0.061 in its last earnings report, beating expectations of -€0.072. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in DE:U5P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.32 (196.79% Upside)
€3.32 (196.79% Upside)
Insider Transactions
Bought Shares
Worth €1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
U5P Stock 12 Month Forecast
Average Price Target
€3.32
▲(196.79% Upside)